Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 177 publications
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.
Journal: Leukemia
Published: May 09, 2026
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.
Journal: Expert opinion on investigational drugs
Published: April 23, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Journal: Expert opinion on biological therapy
Published: March 17, 2026
Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Journal: Expert opinion on emerging drugs
Published: October 30, 2025
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Journal: Nature medicine
Published: October 03, 2025
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Journal: Nature communications
Published: August 01, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions.
Journal: Expert opinion on investigational drugs
Published: July 14, 2025
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy.
Journal: Nature communications
Published: February 02, 2025
Last Updated: 09/26/2026